Lalhmangaihzuala Samson, Vanlaldinpuia Khiangte, Khiangte Vanlalngaihawma, Laldinpuii Zathang, Liana Thanhming, Lalhriatpuia Chhakchhuak, Pachuau Zodinpuia
Department of Chemistry, Pachhunga University College, Mizoram University, Aizawl, Mizoram, 796001, India.
Department of Chemistry, Mizoram University, Tanhril, Aizawl, Mizoram, 796004, India.
Mol Divers. 2024 Dec;28(6):4553-4579. doi: 10.1007/s11030-024-10810-2. Epub 2024 Mar 30.
Carbohydrates, one of the most abundant biomolecules found in nature, have been seen traditionally as a dietary component of foods. Recent findings, however, have unveiled their medicinal potential in the form of carbohydrates-derived drugs. Their remarkable structural diversity, high optical purity, bioavailability, low toxicity and the presence of multiple functional groups have positioned them as a valuable scaffold and an exciting frontier in contemporary therapeutics. At present, more than 170 carbohydrates-based therapeutics have been granted approval by varying regulatory agencies such as United States Food and Drug Administration (FDA), Japan Pharmaceuticals and Medical Devices Agency (PMDA), Chinese National Medical Products Administration (NMPA), and the European Medicines Agency (EMA). This article explores an overview of the fascinating potential and impact of carbohydrate-derived compounds as pharmacological agents and drug delivery vehicles.
碳水化合物是自然界中最丰富的生物分子之一,传统上被视为食物的饮食成分。然而,最近的研究结果揭示了它们以碳水化合物衍生药物的形式所具有的药用潜力。它们显著的结构多样性、高光学纯度、生物利用度、低毒性以及多个官能团的存在,使其成为当代治疗学中有价值的支架和令人兴奋的前沿领域。目前,已有170多种基于碳水化合物的治疗药物获得了不同监管机构的批准,如美国食品药品监督管理局(FDA)、日本药品和医疗器械管理局(PMDA)、中国国家药品监督管理局(NMPA)以及欧洲药品管理局(EMA)。本文概述了碳水化合物衍生化合物作为药理剂和药物递送载体的迷人潜力和影响。